On October 4, 2021, IVIEW Therapeutics, Inc. closed the transaction. The company raised $31.981668 million in the transaction. The company received has raised $25 million form new and existing investors in its final tranche.

This round was led by new investor Proxima Ventures, and included new investors Shenzhen Co-win Venture Capital Investments Limited, Zhejiang Jiufeng Capital Management Co., Ltd., Jun Yuan Capital, Hangzhou Naxin Capital, Haitian (HK) Co., BioAdvance, and existing investors including Share Capital Partners, Zhejiang Huahai Pharmaceutical Co., Ltd. and Alpha Bioventure.